Phase Il
`
`Study of Gral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis
`
`NewsRoom
`
`1/9/06 Bus. Wire 13:30:00
`
`Business Wire
`
`Copyright © 2006 Business Wire
`
`January 9, 2006
`
`PhaseII Study of Oral Compound BG-12 Meets Primary Endpuint in Multiple Sclerosis
`
`BIOWIRE2K CAMBRIDGE, Mass. & LUCERNE, Switzerland--(BUSINESS WIRE)--Jan. 9, 2006--Biogen Idec
`(NASDAQ: BIIB) and Fumapharm AG today announced that a Phase II study designed to evaluate the efficacy and
`safety of BG-12, an oral fumarate, in patients with relapsing-remitting multiple sclerosis (MS) metits primary endpoint.
`Treatment with BG-12 led to a statistically significant reduction in the total number of gadolinium-enhancing brain
`lesions as measured by MRI with six months of treatment versus placebo. This Phase II multi-center, double-blind,
`placebo-controlled study enrolled approximately 250 patients at sites in 10 countries in Europe.
`
`About Biogen Idec
`
`leader in the
`Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global
`development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries
`into advances in human healthcare. For press releases and additional information about the company, please visit http://
`www.biogenidec.com.
`
`About Fumapharm AG
`
`Fumapharm haslicensed exclusive worldwide rights to develop and market BG-12 to Biogen Idec. Fumapharm is a
`privately held pharmaceutical company headquartered in Lucerne, Switzerland. For more information, please visit http://
`www.fumapharm.ch.
`
`CONTACT: Biogen Idec MEDIA CONTACT: AmyBrockelman, 617-914-6524 Senior Manager, Public Affairs or
`INVESTOR CONTACT:Oscar Velastegui, 617-679-2812 Senior Manager, Investor Relations
`KEYWORD: MASSACHUSETTS SWITZERLAND INTERNATIONAL LATIN AMERICAEUROPE
`INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGYPRODUCT
`SOURCE: Biogen Idec
`
`---- Index References -—-
`
`Company: BIOGEN IDEC INC
`
`News Subject: (Major Corporations (1MA93))
`
`Industry: (Pharmaceuticals & Biotechnology (1PH13); Immunology (1 IM66}; Muscular & Neuromuscular Disease
`(IMUS0), Manufacturing (1 MA74); Biopharmaceuticals (1 B113), Healthcare 1 HEOG): Allergy & Immunology (1AL96):
`
`Sawai (IPR2019-00789), Ex. 1005, p. 001
`
`

`

`Phase ll Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerasis
`
`Neurology (1NE95); Multiple Sclerosis & Demyelination (1MU88); Internal Medicine (1IN54), Healthcare Practice
`Specialties (MHE49))
`
`Region: (Americas (1AM92); North America (1NO39); Western. Europe (1WE41); Latin America (1LA15), Europe
`(LEU83); USA (1US73); Central Europe (1CES0); Switzerland (18W77))
`
`Language: EN
`
`Other Indexing: (AG; BIOGEN IDEC; FUMAPHARM; FUMAPHARM AG; NASDAQ:BIIB) (Amy Brockelman;
`Osear Velastegui; Phase; Public Affairs)
`
`Keywords: MASSACHUSETTS SWITZERLAND INTERNATIONAL LATIN AMERICAEUROPE (f);
`(PHARMACEUTICAL MEDICAL BIOTECHNOLOGY PRODUCT)
`
`Ticker Symbol: NASDAQ: BIIB
`
`Word Count: 331
`
` Endo Document
`
`NewsRoom
`
`Sawai (IPR2019-00789), Ex. 1005, p. 002
`
`